FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2766411327> ?p ?o ?g. }

• W2766411327 endingPage "595" @default.
• W2766411327 startingPage "591" @default.
• W2766411327 abstract "No standard therapy is established for metastatic uveal melanoma. Liver involvement in uveal melanoma may lead to organ impairment, which represents a common cause of death. Tumor shrinkage might improve survival by delaying hepatic failure. Since the combination of cisplatin, vinblastine, dacarbazine allowed a high response rate in metastatic cutaneous melanoma, we explored efficacy and safety of this regimen in unresectable liver metastases of uveal melanoma. In the present phase II study we administered intravenously cisplatin (80 mg/mq, day 1), dacarbazine (250 mg/mq/day, days 1-3), vinblastine (2 mg maximum, day 1) every 21 days as first line treatment for patients with unresectable metastases of uveal melanoma and BRAF wild type. Primary endpoint was objective response rate; overall survival (OS), progression-free survival and toxicity were secondary endpoints. Partial responses were observed in five (20%) patients, stable disease in 12 (48%) patients; disease control rate was 68%. Median OS of all the patients was 13 months, median progression free survival was 5.5 months. OS of responding patients was 21 months; OS of patients with disease control was 18 months, significantly longer than survival of progressing patients (7 months, P=0.0003). Five (20%) patients experienced grade 3-4 toxicity. Combination of cisplatin, vinblastine and dacarbazine was feasible and demonstrate both an interesting objective response rate and a survival benefit for patients achieving a disease control. This regimen could be considered for patients with good performance status and unresectable liver limited disease." @default.
• W2766411327 created "2017-11-10" @default.
• W2766411327 creator A5006457492 @default.
• W2766411327 creator A5012446712 @default.
• W2766411327 creator A5018194394 @default.
• W2766411327 creator A5023798303 @default.
• W2766411327 creator A5041690302 @default.
• W2766411327 creator A5049098422 @default.
• W2766411327 creator A5059201916 @default.
• W2766411327 creator A5080721675 @default.
• W2766411327 date "2017-12-01" @default.
• W2766411327 modified "2023-09-30" @default.
• W2766411327 title "Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study" @default.
• W2766411327 cites W1969624479 @default.
• W2766411327 cites W1975909997 @default.
• W2766411327 cites W1980664511 @default.
• W2766411327 cites W1991933930 @default.
• W2766411327 cites W2000255330 @default.
• W2766411327 cites W2005576578 @default.
• W2766411327 cites W2025029236 @default.
• W2766411327 cites W2030929275 @default.
• W2766411327 cites W2038434969 @default.
• W2766411327 cites W2055835855 @default.
• W2766411327 cites W2057663047 @default.
• W2766411327 cites W2069805376 @default.
• W2766411327 cites W2069926898 @default.
• W2766411327 cites W2105214798 @default.
• W2766411327 cites W2110920908 @default.
• W2766411327 cites W2127644935 @default.
• W2766411327 cites W2140033254 @default.
• W2766411327 cites W2152897456 @default.
• W2766411327 cites W2167255026 @default.
• W2766411327 cites W2170033239 @default.
• W2766411327 cites W2320786076 @default.
• W2766411327 cites W2324146158 @default.
• W2766411327 cites W2342956596 @default.
• W2766411327 cites W2515516401 @default.
• W2766411327 doi "https://doi.org/10.1097/cmr.0000000000000401" @default.
• W2766411327 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29076951" @default.
• W2766411327 hasPublicationYear "2017" @default.
• W2766411327 type Work @default.
• W2766411327 sameAs 2766411327 @default.
• W2766411327 citedByCount "28" @default.
• W2766411327 countsByYear W27664113272018 @default.
• W2766411327 countsByYear W27664113272019 @default.
• W2766411327 countsByYear W27664113272020 @default.
• W2766411327 countsByYear W27664113272021 @default.
• W2766411327 countsByYear W27664113272022 @default.
• W2766411327 countsByYear W27664113272023 @default.
• W2766411327 crossrefType "journal-article" @default.
• W2766411327 hasAuthorship W2766411327A5006457492 @default.
• W2766411327 hasAuthorship W2766411327A5012446712 @default.
• W2766411327 hasAuthorship W2766411327A5018194394 @default.
• W2766411327 hasAuthorship W2766411327A5023798303 @default.
• W2766411327 hasAuthorship W2766411327A5041690302 @default.
• W2766411327 hasAuthorship W2766411327A5049098422 @default.
• W2766411327 hasAuthorship W2766411327A5059201916 @default.
• W2766411327 hasAuthorship W2766411327A5080721675 @default.
• W2766411327 hasConcept C126322002 @default.
• W2766411327 hasConcept C141071460 @default.
• W2766411327 hasConcept C143998085 @default.
• W2766411327 hasConcept C2776283816 @default.
• W2766411327 hasConcept C2776694085 @default.
• W2766411327 hasConcept C2777132456 @default.
• W2766411327 hasConcept C2777658100 @default.
• W2766411327 hasConcept C2778239845 @default.
• W2766411327 hasConcept C2778822529 @default.
• W2766411327 hasConcept C2780964509 @default.
• W2766411327 hasConcept C2781413609 @default.
• W2766411327 hasConcept C31760486 @default.
• W2766411327 hasConcept C502942594 @default.
• W2766411327 hasConcept C71924100 @default.
• W2766411327 hasConcept C90924648 @default.
• W2766411327 hasConceptScore W2766411327C126322002 @default.
• W2766411327 hasConceptScore W2766411327C141071460 @default.
• W2766411327 hasConceptScore W2766411327C143998085 @default.
• W2766411327 hasConceptScore W2766411327C2776283816 @default.
• W2766411327 hasConceptScore W2766411327C2776694085 @default.
• W2766411327 hasConceptScore W2766411327C2777132456 @default.
• W2766411327 hasConceptScore W2766411327C2777658100 @default.
• W2766411327 hasConceptScore W2766411327C2778239845 @default.
• W2766411327 hasConceptScore W2766411327C2778822529 @default.
• W2766411327 hasConceptScore W2766411327C2780964509 @default.
• W2766411327 hasConceptScore W2766411327C2781413609 @default.
• W2766411327 hasConceptScore W2766411327C31760486 @default.
• W2766411327 hasConceptScore W2766411327C502942594 @default.
• W2766411327 hasConceptScore W2766411327C71924100 @default.
• W2766411327 hasConceptScore W2766411327C90924648 @default.
• W2766411327 hasIssue "6" @default.
• W2766411327 hasLocation W27664113271 @default.
• W2766411327 hasLocation W27664113272 @default.
• W2766411327 hasOpenAccess W2766411327 @default.
• W2766411327 hasPrimaryLocation W27664113271 @default.
• W2766411327 hasRelatedWork W2008828217 @default.
• W2766411327 hasRelatedWork W2044675217 @default.
• W2766411327 hasRelatedWork W2088035700 @default.
• W2766411327 hasRelatedWork W2121713339 @default.
• W2766411327 hasRelatedWork W2152169833 @default.

• next